Eisai shares rose sharply Thursday morning after the U.S. Food and Drug Administration’s review memo on Leqembi raised expectations for full approval of the Alzheimer’s drug.
You are here: Home / Top Stories / Dow Jones Newswires: Eisai shares rise as FDA memo raises hopes for full approval of Alzheimer’s drug